spr

SPI-112, the SPI-112 methyl ester analog, can inhibit cellular Shp2 PTP activity. SPI-112 bound to Shp2 by surface plasmon resonance (SPR) and displayed competitive inhibitor kinetics to Shp2.

SPR inhibitor 3 is an effective sepiapterin reductase inhibitor. SPR inhibitor 3 decreases neuropathic and inflammatory pain through a reduction of BH4 levels. SPR inhibitor 3 shows a high binding affinity to human SPR in a cell-free assay (IC50=74 nM) an

SPR-00305 is a novel potent inhibitor of the mvfr pathway

Spr 210 is an aldose reductase (AR) inhibitor with potential uses as a therapeutic agent for preventing and improving some diabetic complications.

Esprolol (ACC-9369 free base) is a novel β-adrenergic receptor antagonist for the study of exertional angina.

Ispronicline (TC-1734) An orally active, selective, and potent α4β2 nAChR partial agonist with antidepressant, neuroprotective, and long-lasting cognitive effects.Ispronicline has a high affinity for the α4β2 nAChR with a Ki= 11 nM.

SPR741 acetate is a cationic peptide derived from polymyxin B. It exhibits antimicrobial activity against gram-negative bacteria by inhibiting severe gram-negative bacterial sensory by increasing the permeability of the outer membrane of gram-negative bacteria.SPR741 acetate is often used in conjunction with antibiotics for the treatment of a number of diseases.

SPR206 is a polymyxin analogue and an important class of antibiotic for the treatment of bacterial infections due to multidrug resistant Gram-negative pathogen.

SPR719 is an inhibitor of gyrase B, has bactericidal activity.

SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate efficiently combats bacterial infections, displaying significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against [Pseudomonas aeruginosa Pa14] and [Acinetobacter baumannii NCTC13301].

SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule.

SPR741, formerly NAB741 (12), is a cationic peptide derived from polymyxin B and is one such potentiator molecule that is under development for the treatment of serious Gram-negative bacterial infections.

SPRC is a novel synthetic molecule exerting antioxidant effects via elevating the generation of endogenous H2S. SPRC activates Gp130-mediated STAT3 and prevents doxorubicin-induced cardiotoxicity.

Esprolol is a β-adrenergic receptor antagonist.

Sprodiamide is a magnetic susceptibility-based MRI contrast agent.

14-Hydroxy sprengerinin C, a natural product derived from Ophiopogon japonicus.

Onfasprodil, a negative allosteric modulator of NR2B, has been identified as a potential compound for researching Alzheimer's disease. This compound, in combination with a GABA receptor regulator.[1]

SPR7 is a potent and selective rhodesain inhibitor (Ki: 0.51 nM). SPR7 exhibited antiparasitic effects against T. b. brucei (EC50: 1.65 μM).

Ispronicline, also known as AZD3480; TC 1734; TC-0173, and RJR 1734, is a alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. Ispronicline is potentially useful for the treatment of attention-deficit hyperactivity disorder in adults.

SPR519 is a potent dual inhibitor of PI3Kα and mTOR kinases with IC50 (PI3Kalpha) = 30 nM and IC50 (mTOR) = 10 nM. SPR519 exhibits an EC50 of low sub-micromolar range among various tested cancer cell lines such as A2780 (0.23 μM), PC3 (0.48 μM), and SKOV3 (0.50 μM).

SPR39, a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrates inhibitory Ki values of 0.252 µM for SARS-CoV-2 Mpro, and 3.38 and 7.88 µM for human Cathepsin L (hCatL) and human Cathepsin B (hCatB) respectively. It exhibits antiviral properties and cytotoxicity.

SPR38, a potent inhibitor of the SARS-CoV-2 main protease, exhibits a Ki value of 0.260 μM. Additionally, it effectively inhibits human cathepsin L (hCatL) and human cathepsin B (hCatB), displaying Ki values of 1.92 μM and 11.1 μM, respectively.

SPR41, a potent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibits Ki values of 0.184 µM for SARS-CoV-2 Mpro, 0.252 µM for hCatL, and 14.4 µM for hCatB, demonstrating significant antiviral activity and cytotoxicity.

Insulin peglispro (BIL) represents a basal insulin characterized by a sustained, stable activity pattern. This compound demonstrates enhanced glucose regulation abilities when compared to traditional insulins [1].